December 2016
-
KAER Biotherapeutics gets SBIR grant for development of aerosol therapy for RDS in premature infants
KAER Biotherapeutics has received a $300,000 Small Business Innovation Research (SBIR) grant from the National Heart Lung and Blood Institute of the National Institutes of Health for preclinical development of its SUPRAER aerosol platform for… Read more . . .
-
Led by inhaler device platform designer and supplier Merxin and by Nanopharm, a CRO specializing in inhaled and nasal drugs, a group of companies that offer products and services for OINDP development has come together… Read more . . .
-
The FDA has approved an ANDA for Akorn’s generic azelastine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis in patients 5 years old and older and for vasomotor rhinitis in patients 12 and… Read more . . .
-
A study published May 19, 2019 in the New England Journal of Medicine found that the Symbicort Turbuhaler budesonide/formoterol DPI demonstrated a greater than 50% reduction in the risk of asthma exacerbations in mild asthma… Read more . . .
-
Respivant Sciences has announced dosing of the first patient in the Phase 2b SCENIC trial of its RVT-1601 cromolyn sodium inhalation solution for the treatment of cough in idiopathic pulmonary fibrosis (IPF) patients. Respivant was… Read more . . .
-
UCB said that the FDA has approved an NDA for Nayzilam midazolam nasal spray (formerly USL261) for the treatment of seizure clusters in epilepsy patients aged and older. UCB acquired the nasal spray from former… Read more . . .
-
MannKind Corporation has announced that signed a marketing and distribution agreement with Australasian Medical & Scientific Ltd division AMSL Diabetes for commercialization of Afrezza inhaled insulin in Australia. AMSL Diabetes will take responsibility for getting… Read more . . .
-
Aptar Pharma has announced that GSK’s Otrivin xylometazoline nasal spray, which is delivered via Aptar’s Freepod multidose nasal spray pump, won a 2019 WorldStar Packaging Award in the Medical & Pharma category. The WorldStar Packaging… Read more . . .
-
Lonza has announced the launch of a new DPI capsule portfolio called Capsugel Zephyr “to meet the growing need for customized solutions for optimal pulmonary drug delivery.” The new DPI capsules are customizable and can… Read more . . .
-
Over 500 OINDP specialists attended RDD Europe 2019 in Estoril, Portugal, May 7-10, making the conference the biggest RDD Europe meeting ever, the organizers said. Carolyn Penot of Aptar Pharma, which co-organizes RDD Europe said,… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK